Daptomycin is a treatment of last resort for serious infections caused by drug-resistant Gram-positive 31 pathogens such as methicillin-resistant Staphylococcus aureus. We have shown recently that S. aureus 32 can evade daptomycin by releasing phospholipid decoys that sequester and inactivate the antibiotic, 33 leading to treatment failure. Since phospholipid release occurs via an active process we hypothesised 34 that it could be inhibited, thereby increasing daptomycin efficacy. To identify opportunities for 35 therapeutic interventions that block phospholipid release, we first determined how the host 36 environment influenced the release of phospholipids and inactivation of daptomycin by S. aureus. The 37 addition of certain host-associated fatty acids to the growth medium enhanced phospholipid release. 38
Introduction
The ability of released membrane phospholipids to inactivate daptomycin can be compromised in S. 77 aureus by the quorum-sensing-triggered production of small cytolytic peptides known as the alpha 78 phenol soluble modulins (PSMα) [9] . These peptides appear to compete with daptomycin for the 79 phospholipid and thereby prevent inactivation of the antibiotic [9] . Whilst this may appear 80 paradoxical, many invasive infections are caused by S. aureus strains defective for PSMα production 81 due to defects in the Agr quorum-sensing system that triggers expression of the peptides [11] [12] [13] . 82 Furthermore, serum apolipoproteins inhibits Agr and sequesters PSMs, which would be expected to 83 allow wild-type bacteria to inactivate daptomycin [14] [15] [16] [17] . 84
The mechanism by which daptomycin triggers phospholipid release is currently undefined. However, 85
we have shown that it is an active process that requires energy, as well as protein, cell wall and lipid 86 biosynthesis [9, 10] . The requirement for fatty acid biosynthesis for phospholipid release is important 87 because it raises the prospect of targeting this process to enhance daptomycin efficacy. We have 88
shown previously that inhibition of the FabF component of the FASII fatty acid synthetic pathway, 89 using the antibiotic platensimycin, completely blocked phospholipid release [9, 10] . Whilst 90 platensimycin is unsuitable as a therapeutic drug due to poor pharmacological properties, the FabI 91 inhibitor AFN-1252 shows more promising characteristics and a pro-drug variant is currently 92 4 undergoing phase 2 clinical trials [18, 19] . However, despite excellent in vitro activity, the therapeutic 93 value of inhibitors of fatty acid synthesis as mono-therapeutic agents has attracted much debate 94 [20, 21] . Several bacteria, including S. aureus, can utilise fatty acids present in the host to generate 95 phospholipids [21] [22] [23] [24] . Although wild-type S. aureus strains cannot fully substitute exogenous fatty 96 acids for endogenous fatty acids synthesised via FASII, there is evidence that some clinical isolates 97 have acquired mutations that enable them to fully bypass endogenous fatty acid biosynthesis by 98 utilising host-derived fatty acids [22, 25, 26] . Furthermore, in vitro experimentation suggests that the 99 acquisition of such mutations is dependent upon the presence of host-associated fatty acids, which 100 means that the frequency at which resistance to AFN-1252 emerges in vivo may have been under-101 estimated [25, 26] . As such, the long-term viability of fatty acid synthesis inhibitors, such as AFN-1252, 102 as mono-therapeutic antibacterial drugs is unclear and their ability to block daptomycin-induced 103 phospholipid release in the presence of exogenous fatty acids undetermined [20, 21] . 104 Therefore, the aims of this work were to understand how the availability of fatty acids in the host 105 influences the production of phospholipid decoys and determine whether AFN-1252 could be used in 106 combination with daptomycin to provide a viable approach to combatting MRSA infection. 107
108

Results
109
Exogenous fatty acids modulate daptomycin-induced phospholipid release 110
The release of membrane phospholipids in response to daptomycin occurs via an active process that 111 requires de novo phospholipid biosynthesis [9] . Whilst S. aureus has an endogenous fatty acid 112 biosynthetic pathway (FASII), it can also incorporate fatty acids from the host into membrane 113 phospholipid production [21] [22] [23] [24] . Therefore, it was hypothesised that host-derived fatty acids would 114 contribute to the production of lipids required for daptomycin-induced phospholipid release. 115
To enable accurate measurements of phospholipid release, these experiments were done in TSB 116 containing, or not, one of several different fatty acids found in normal human serum [27] . Although 117 the concentrations of each lipid species in serum varies, we employed a single concentration of 20 μM 118 to enable direct comparison. Furthermore, the S. aureus ΔagrA mutant was used to avoid the Agr 119 system compromising daptomycin inactivation [9] . 120
As reported previously, exposure of the S. aureus USA300 ΔagrA mutant to daptomycin in the absence 121 of exogenous fatty acids resulted in the release of phospholipids into the extracellular space ( Fig. 1A ) 122
[9]. Supplementation of the TSB growth medium with linoleic acid had no effect on the rate or quantity 123 of phospholipid released, whilst the presence of myristic or palmitic acids resulted in a small increase 124 5 in the quantity of phospholipids released at the latest time point (Fig. 1A) . By contrast, the presence 125 of oleic or lauric acids significantly enhanced both the rate and quantity of phospholipids released, 126 relative to TSB without fatty acids ( Fig. 1A) . 127
As reported previously, in the absence of exogenous fatty acids, phospholipids released from the 128 ΔagrA mutant resulted in the inactivation of daptomycin ( Fig. 1B) [9]. The increased release of 129 phospholipids from bacteria incubated with oleic or lauric acids resulted in a slightly faster rate of 130 daptomycin inactivation, whilst the presence of linoleic, palmitic or myristic acids reduced the rate of 131 daptomycin inactivation ( Fig. 1B) . Of note, S. aureus failed to fully inactivate daptomycin in the 132 presence of palmitic or linoleic acids, indicating that exogenous fatty acids can retard as well as 133 promote the rate of phospholipid-mediated daptomycin inactivation ( Fig. 1B) . 134
In keeping with the effect of individual fatty acids on daptomycin inactivation, the presence of oleic 135 or lauric acid promoted bacterial survival 10-fold above that seen for S. aureus incubated without fatty 136 acids by 8 h. By contrast, the presence of palmitic or linoleic acids reduced survival approximately 10-137 fold, whilst myristic acid had no effect (Fig. 1C) . 138
Taken together, these experiments demonstrated that certain fatty acids, such as oleic and lauric 139 acids, can significantly enhance phospholipid release, whilst others are inhibitory or have no effect. 140 141
Serum albumin restricts the utilisation of oleic acid by S. aureus for phospholipid release 142
Having established that fatty acids can modulate phospholipid release in TSB, we wanted to determine 143 whether their presence in the host context had a similar effect. To do this, we firstly supplemented 144 TSB with 50% delipidated human serum, which is deficient for fatty acids. Similarly to what was seen 145 in TSB alone, exposure of the ΔagrA mutant to daptomycin in TSB containing 50% delipidated human 146 serum resulted in an initial fall in CFU counts, followed by a period of recovery ( Fig. 2A ). However, in 147 contrast to our observations for TSB ( Fig. 1C ), the addition of oleic acid to TSB containing 50% 148 delipidated serum had no effect on bacterial survival ( Fig. 2A ). In keeping with these data, the 149 presence of oleic acid had no effect on the rate at which the bacteria inactivated daptomycin (Fig. 2B) . 150
This indicated that the ability of S. aureus to use oleic acid to promote phospholipid release was 151 restricted by a factor found in serum but not TSB, although this was not quantified directly as serum 152 proteins interfered with the dye-based assay system. 153
Fatty acids present in the bloodstream are typically bound to serum albumin, which acts as a 154 carrier protein [28] . To determine whether the presence of this host protein restricted the availability 155 of oleic acid for use in phospholipid release-mediated inactivation of daptomycin, the S. aureus ΔagrA 156 6 mutant was exposed to daptomycin in TSB containing oleic acid and human serum albumin (HSA). By 157 contrast to TSB only, the presence of HSA completely abrogated the increased rate of daptomycin 158 inactivation and bacterial survival observed on supplementation with oleic acid, presumably due to 159 sequestration of the fatty acid by the protein (Fig. 2C,D) . Therefore, the sequestration of oleic acid by 160 serum albumin prevents its use by S. aureus to promote daptomycin-induced phospholipid release. 161
162
AFN-1252 blocks daptomycin-induced phospholipid release 163
The finding that HSA prevented the use of exogenous oleic acid by S. aureus to promote the rate of 164 daptomycin inactivation indicated that this process is likely to be entirely dependent upon the FASII 165 pathway in vivo. AFN-1252 is a FASII pathway inhibitor which blocks FabI and has shown potent activity 166 against S. aureus in both pre-clinical and clinical testing [18, 19] . Based on our previous findings [9], 167 and the data described above, we hypothesised that AFN-1252 would enhance daptomycin activity 168 against S. aureus by blocking the production of phospholipid decoys. 169
To test this, the S. aureus ΔagrA mutant was exposed to AFN-1252 (0.15 µg ml -1 ) in the 170 absence or presence of daptomycin. Alone, AFN-1252 showed bacteriostatic activity (<10-fold drop in 171 CFU counts after 8h) ( Fig. 3A) . As described previously, CFU counts of the S. aureus ΔagrA mutant 172 exposed to daptomycin fell initially, before recovering due to the release of phospholipids that led to 173 the inactivation of the antibiotic (Fig. 3A ,B,C) [9] . However, when the S. aureus ΔagrA mutant was 174 exposed to daptomycin in the presence of AFN-1252, there was a >500-fold drop in CFU counts, with 175 no recovery of the bacterial population ( Fig. 3A ). Further analysis revealed that AFN-1252 almost 176 completely blocked daptomycin-induced phospholipid release and the associated daptomycin 177 inactivation ( Fig. 3B,C) , providing an explanation for the synergy observed when these antibiotics were 178 used in combination. 179
Whilst our data indicated that HSA restricts the utilisation of fatty acids for phospholipid 180 release ( Fig. 2C,D) , we considered the possibility that some unbound lipids may arise during infection 181 because of damage to host tissues. Therefore, we repeated the experiments described in Figures 182 3A,B,C in the presence of oleic acid without HSA, which had previously been shown to significantly 183 promote phospholipid release (Fig. 1A) . The data generated from these experiments were almost 184 identical to those from experiments done in the absence of the fatty acid ( Fig. 3D ,E,F). AFN-1252 185 showed clear synergistic activity when used in combination with daptomycin by blocking phospholipid 186 release, even in the presence of unbound oleic acid (Fig. 3E ). This resulted in the maintenance of 187 daptomycin activity and a sustained killing effect on S. aureus (Fig. 3D ,F).
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Together, these data demonstrate that AFN-1252 prevents the production of phospholipid 189 decoys, even in the presence of exogenous fatty acids which would otherwise enhance phospholipid 190 release. Therefore, AFN-1252 prevents subsequent recovery of the population, enhancing the ability 191 of daptomycin to kill S. aureus 192 Exogenous fatty acids enable emergence of resistance to AFN-1252 193
The data described above indicated that the FASII inhibitor AFN-1252 in combination with daptomycin 194 may be a promising therapeutic approach. However, it has been reported that S. aureus can acquire 195 resistance to FASII inhibitors in the presence of exogenous fatty acids [25, 26] . To confirm that these 196 findings applied to AFN-1252, 10 parallel cultures of the USA300 ΔagrA mutant were repeatedly 197 challenged with AFN-1252 (0.15 µg ml -1 ) in the absence or presence of a physiologically relevant fatty 198 acid cocktail as described previously [26] . Given the impact of HSA on daptomycin inactivation, parallel 199 assays were done with or without the serum protein. After each exposure, bacterial susceptibility to 200 AFN-1252 was determined by broth microdilution assays to establish the MIC. 201
As expected from previous reports, there was very little change in bacterial growth ( Fig. 4A ) or MIC 202 ( Fig. 4B ) when S. aureus was repeatedly exposed to AFN-1252 in the absence of fatty acids [26] . 203
However, in keeping with previous work, by the third round of exposure to AFN-1252 in the presence 204 of fatty acids, with or without HSA, S. aureus was able to replicate in the presence of the antibiotic 205 ( Fig. 4A) [26]. The ability of S. aureus to grow in the presence of AFN-1252 after repeated exposure to 206 the antibiotic in the presence of fatty acids, regardless of the presence of HSA, correlated well with 207 data from subsequent MIC assays ( Fig. 4C,D) . When fatty acids were included in the MIC assays, there 208 was a significant and large increase in the MICs of most cultures from 0.03125 µg ml -1 to more than 209 16 µg ml -1 (>512-fold) for bacteria that were exposed to AFN-1252 in the presence of exogenous fatty 210 acids, regardless of the presence of HSA (Fig. 4C,D) . Together, these data confirmed previous work 211
showing that repeated exposure of S. aureus to AFN-1252 in the presence of exogenous fatty acids 212 facilitated the emergence of fatty acid-dependent resistance to this antibiotic [26] . 213 214
Daptomycin prevents fatty acid-dependent emergence of resistance to AFN-1252 215
Having confirmed that AFN-1252 resistance can arise in the presence of fatty acids, the next objective 216 was to test whether combination therapy with daptomycin could prevent this. Therefore, the 217 repeated antibiotic exposure experiment described above was re-run in the presence of daptomycin 218 (20 µg ml -1 ) and in the absence or presence of exogenous fatty acids and HSA. As expected from 219 previous data (Fig. 3) , bacterial killing with daptomycin/AFN-1252 combination therapy was highly 220 effective for the first two exposures, where bacterial survival was 1% or less after 8 hours. An increase 221 in bacterial survival was observed on the third exposure, but bacterial growth was still inhibited with 222 8 CFU counts not exceeding that of the original inoculum (Fig. 5A ). Furthermore, this increase in survival 223 was independent of the presence of fatty acids (Fig. 5A) . 224
To determine whether daptomycin prevented the emergence of resistance to AFN-1252, MICs were 225 determined by broth microdilution. By contrast to experiments with AFN-1252 alone, repeated 226 exposure of S. aureus to AFN-1252 in the presence of daptomycin did not lead to an increase in MIC 227 of the FASII inhibitor, even in the presence of fatty acids (Fig. 5B,C,D) . Neither was there any increase 228 in the daptomycin MIC (Fig. 5E,F,G) . Together, these data demonstrate that daptomycin prevented 229 the emergence of fatty acid-dependent resistance to AFN-1252 when the two antibiotics were used 230 in combination. 231
Despite the increase in bacterial survival on the third exposure, this did not exceed the original 232 inoculum (Fig. 5A) , and the unchanged MIC values (Fig. 5B ,C,D,E,F,G) indicated that AFN-1252 and 233 daptomycin still had bacteriostatic activity. It is therefore likely that this increase in survival after 3 234 exposures was due to the acquisition of tolerance to daptomycin, which is consistent with a previous 235 study [29] . 236
237
AFN-1252 blocks daptomycin-induced phospholipid release in AFN-1252-resistant strains 238
Having established that the combination of daptomycin and AFN-1252 prevented the emergence of 239 AFN-1252 resistance, we next wanted to understand the underlying mechanism. To determine this, 240 individual colonies of AFN-1252 resistant bacteria that had arisen in the presence of fatty acids and 241 the presence or absence of HSA were picked. These were then assessed for survival, phospholipid 242 release and ability to inactivate daptomycin in the absence or presence of fatty acids by comparison 243 with the ΔagrA mutant that had not been exposed to antibiotics. 244
As described above (Fig. 3) , two independent colony picks of the ΔagrA mutant that had not previously 245 been exposed to antibiotics survived exposure to daptomycin by releasing phospholipids that 246 completely inactivated the antibiotic (Fig. 6A,B,C) . However, the presence of AFN-1252 increased the 247 bactericidal activity of daptomycin by preventing phospholipid release and thus preserving the activity 248 of the lipopeptide antibiotic, regardless of the presence of fatty acids (Fig. 6A,B,C) . 249
Next, we assessed the survival of bacteria from 3 independent cultures that had acquired resistance 250 to AFN-1252 during exposure to the antibiotic in the presence of fatty acids but not HSA (AFN-1252 251 R). Of these 3 isolates, 2 were more susceptible to daptomycin than the ΔagrA mutant, apparently 252 because they released lower levels of phospholipids that failed to fully inactivate the lipopeptide 253 antibiotic (Fig. 6D,E,F) . The remaining isolate reduced daptomycin activity by 70%, explaining its 254 enhanced survival in the presence of daptomycin relative to the other 2 isolates. However, the 255 9 presence of AFN-1252 completely abolished the ability of any of these isolates to inactivate 256 daptomycin, even when exogenous FAs were present (Fig. 6D,E,F) . 257
We then examined S. aureus isolates from 3 independent cultures that had acquired resistance to 258 AFN-1252 during exposure to the antibiotic in the presence of fatty acids and HSA (AFN-1252 R HSA). 259
Survival of these three AFN-1252-resistant isolates after exposure to daptomycin alone was not 260 significantly lower than that seen for the AFN-1252-sensitive ΔagrA mutant. This was due to the 261 release of sufficient phospholipid to inactivate all or most of the daptomycin that the bacteria were 262 incubated with (Fig. 6G, H, I) . However, despite the ability of these bacteria to grow in the presence 263 of AFN-1252 when exogenous FAs were available, the FASII inhibitor almost completely blocked 264 daptomycin-induced phospholipid release from all three isolates, even when the FA cocktail was 265 present (Fig. 6G,H,I) . 266
Together, these data reveal that fatty acid-enabled AFN-1252 resistance results in a reduced ability to 267 release phospholipids in response to daptomycin (Fig. 6E, H) . Furthermore, although these strains 268
were deemed resistant to AFN-1252, daptomycin-induced phospholipid release was inhibited by the 269 FASII inhibitor, even in the presence of exogenous fatty acids (Fig. 6F,I The high rate of daptomycin treatment failure warrants efforts to identify new approaches to 278 enhance therapeutic outcomes. In this report we provide evidence that combining daptomycin with 279 the fatty acid biosynthesis inhibitor AFN-1252 provides synergistic activity against S. aureus and 280 reduces the frequency of drug resistance. 281
It is increasingly clear that the host environment modulates the susceptibility of bacterial 282 pathogens to antibiotics due to the scarcity of nutrients and the induction of stress responses that 283 result in changes in bacterial physiology [30, 31] . Serum contains high concentrations of fatty acids, 284 which can be exploited by S. aureus to produce phospholipids, reducing the metabolic costs associated 285 with membrane biogenesis [21, 23] . In keeping with this, we found that the presence of specific 286 exogenous fatty acids, such as oleic or lauric acids, enhanced phospholipid release in response to 287 daptomycin. However, S. aureus has strict requirements for the type of fatty acids that it can 288 incorporate and, at least for wild-type strains, each phospholipid must have at least one fatty acid tail 289 synthesised endogenously via FASII [32] . This requirement for FASII-mediated fatty acid biosynthesis 290 to generate phospholipids was underlined by the ability of AFN-1252 to completely block phospholipid 291 decoy release, regardless of the presence of oleic acid [32] . This provides evidence that 292 daptomycin/AFN-1252 combination therapy would not be compromised by the availability of fatty 293 acids in the host. 294
Whilst some exogenous fatty acids can be used for phospholipid biosynthesis during 295 staphylococcal growth, it appears that their contribution to daptomycin-induced phospholipid release 296 is severely compromised by the presence of serum albumin, which sequesters the fatty acids [28]. As 297 described above, there is clear evidence that S. aureus can partially substitute endogenous fatty acid 298 biosynthesis for exogenous host-derived fatty acids in the generation of phospholipids. However, our 299 data demonstrate that the presence of serum albumin reduces the efficiency of this process 300 sufficiently to prevent their use in daptomycin-induced phospholipid release, which must occur rapidly 301 if the bacteria are to survive. 302
The successful clinical development of AFN-1252 would be a welcome addition to the arsenal 303 of anti-staphylococcal antibiotics. However, although wild-type bacteria are dependent upon the 304 endogenous FASII pathway to generate fatty acids for phospholipid biosynthesis, there is evidence 305 that this is not the case in strains that have acquired mutations within the acc or fabD lipid biosynthetic 306 gene loci [25, 26] . These mutants can bypass FASII-mediated fatty acid production, conferring 307 resistance to AFN-1252 in the presence of exogenous fatty acids [25, 26] . It has been suggested that 308 FASII bypass could compromise the long-term therapeutic viability of FASII inhibitors such as AFN-309 1252, a view that is supported by the identification of clinical isolates that are able to resist AFN-1252 310 in the presence of exogenous fatty acids [25] . However, early clinical studies have shown that AFN-311 1252 can successfully treat skin and soft tissue infections, albeit in a relatively small number of patients 312 [18] . Therefore, it remains to be seen whether resistance to AFN-1252 becomes a significant clinical 313 problem. However, given the ability of S. aureus to acquire resistance to antibiotics, it seems prudent 314 to develop therapeutic strategies to prevent or overcome the emergence of resistance to AFN-1252. 315 Our data provide support for the concept of AFN-1252 resistance via fatty acid dependent FASII 316 bypass, but also demonstrate that it can be prevented by the presence of daptomycin, at least in vitro. 317
The combination of AFN-1252 and daptomycin could be described as a mutually-beneficial pairing; 318 whilst AFN-1252 promotes daptomycin activity by blocking phospholipid release, daptomycin 319 enhances AFN-1252 efficacy by preventing the emergence of resistance. This finding contributes to 320 our growing appreciation for the potential of combination therapy approaches to circumvent 321 resistance mechanisms. A well-established example of this is the combination of daptomycin and β-322 11 lactams that target penicillin-binding protein (PBP) 1. In this combination, daptomycin sensitises MRSA 323 to β-lactam antibiotics by reducing the quantity of PBP2a available, whilst β-lactams sensitise S. aureus 324 to daptomycin by increasing binding of the lipopeptide antibiotic to the bacterial membrane [33] [34] [35] [36] . 325
This phenomenon, known as the see-saw effect, significantly promotes killing of S. aureus relative to 326 each of the antibiotics individually and is currently being assessed as a therapeutic option in a clinical 327 trial [37] . 328
Although the combination of daptomycin and AFN-1252 prevented the acquisition of resistance to 329 either antibiotic, we did observe the emergence of tolerance to the lipopeptide antibiotic after the 330 third exposure to the drugs. The acquisition of daptomycin tolerance has been reported previously 331
and was found to occur via increased expression of the dltABCD operon, although the mechanism by 332 which this reduced susceptibility was unclear [29] . Crucially, however, whilst this tolerance phenotype 333 reduces the ability of the daptomycin/AFN-1252 combination to kill S. aureus, the antibiotics are still 334 able to inhibit bacterial growth. 335
In summary, the presence of AFN-1252 prevents the phospholipid-mediated inactivation of 336 daptomycin by S. aureus, whilst daptomycin prevents the fatty-acid dependent emergence of 337 resistance to AFN-1252. Therefore, we propose that the combination of AFN-1252 and daptomycin 338 may have therapeutic value for the treatment of serious MRSA infections. 339 340 341 342 Methods 343
Bacterial strains and growth conditions 344
Staphylococcus aureus strains USA300 wild-type and ΔagrA mutant [9] were grown in tryptic soy broth 345 (TSB) or on tryptic soy agar (TSA). For some assays TSB was supplemented with fatty acids including 346 oleic acid, linoleic acid, palmitic acid, myristic acid or lauric acid (all obtained from Sigma). Since the 347 serum concentrations of these fatty acids vary from 2 μM (lauric acid) to 122 μM (oleic acid) [27] , 348 assays were done with a single concentration (20 μM) within this range. For some assays, HSA was 349 included (10 mg ml -1 ) to sequester fatty acids [22] . Bacteria inoculated onto TSA plates were incubated 350 statically at 37 °C for 15-17 hours in air unless otherwise stated. Liquid cultures were grown in 3 ml 351 broth in 30 ml universal tubes by suspending a single colony from TSA plates, and incubated at 37 °C, 352 with shaking at 180 RPM to facilitate aeration for 15-17 hours to stationary phase. Staphylococcal 353 colony forming units (CFU) were enumerated by serial dilution in sterile PBS and plating of aliquots 354 onto TSA. Bacterial stocks were stored in growth medium containing 20% glycerol at -80 °C. 355 12 356 Antibiotic killing kinetics 357 S. aureus was grown to stationary-phase in 3 ml TSB with shaking (180 RPM) at 37 °C in 30 ml universals 358 as described above. Bacteria were subsequently adjusted to a concentration of ~ 1 x 10 8 bacteria ml -1 359 in fresh TSB containing 0.5 mM CaCl2 before antibiotics were added at the following concentrations: 360 daptomycin (20 μg ml -1 , Tocris), AFN-1252 (0.15 μg ml -1 , Medchemexpress). For some experiments, 361 TSB was supplemented with 50% normal human serum (Sigma), human serum albumin or fatty acids 362 as indicated. Cultures were then incubated at 37 °C with shaking (180 RPM) and bacterial viability 363 determined by CFU counts from samples taken every 2 h for 8 h. 364 365
Daptomycin activity determination 366
The activity of daptomycin during incubation with S. aureus was quantified as described previously 367 [9, 10] . A well of 10 mm was made in TSA plates containing 0.5 mM CaCl2, followed by the spreading 368 of stationary phase wild-type USA300 LAC (60 μl, ~10 6 ml -1 in TSB) across the surface. When AFN-1252 369 was used in assays, TSA was spread with Streptococcus agalactiae COH1 instead of S. aureus as this 370 bacterium is naturally resistant to the FASII inhibitor but susceptible to daptomycin. Thereafter the 371 plate was dried before the wells were filled with filter-sterilised culture supernatant. Plates were then 372 incubated for 16 h at 37 °C before the zone of growth inhibition around the well was measured at 4 373 perpendicular points. To accurately quantify daptomycin activity, a standard plot was generated for 374 the zone of growth inhibition around wells that were filled with TSB supplemented with range of 
Antibiotic resistance selection assay 390
Stationary phase S. aureus was inoculated at ~10 8 CFU ml -1 into 3 ml TSB with 0.5 mM CaCl2 containing 391 antibiotics as specified, for 8 h per exposure. Daptomycin (20 µg ml -1 ) and/or AFN-1252 (0.15 µg ml -1 ) 392 were used singly or in combination. After 8 h, bacterial survival was determined by calculating the 393 fold-change (for assays with the bacteriostatic AFN-1252 only) or percentage-change (for assays with 394 the bactericidal antibiotic daptomycin) in CFU relative to the inoculum. For repeated antibiotic 395 exposure, 1 ml was removed from each culture post-antibiotic exposure, centrifuged (3 min, 17,000 x 396 g) and the resulting pellet washed once in TSB before resuspension in 100 µl TSB. This was used to 397 inoculate 3 ml TSB before incubation for 16 h at 37 o C with shaking (180 RPM) in the absence of 398 antibiotics. Bacterial exposure to antibiotics was then repeated twice for a total of three repeated 399 exposures. In some experiments, the broth was supplemented with a fatty acid cocktail prepared as 400 follows: myristic, palmitic and oleic acid (all from Sigma-Aldrich) were made up to 100 mM in dimethyl 401 sulfoxide (DMSO) as described previously [26] . Where used, the fatty acid cocktail was diluted 1 in 402 2000 in culture medium to obtain a final concentration of 50 µM. In some cases, TSB was also 403 supplemented with human serum albumin (Sigma-Aldrich) at 10 µg ml -1 . 404 405
Determination of antibiotic minimal inhibitory concentrations 406
Antibiotic susceptibility was determined using the broth microdilution procedure as described 407 previously [38] to generate minimal inhibitory concentrations for daptomycin and AFN-1252. 408 Antibiotics were diluted serially in 2-fold steps in TSB containing 0.5 mM CaCl2 in a 96-well microtitre 409 plate to obtain a range of concentrations. In some assays, a fatty acid cocktail (50 µM) was added to 410 the broth as described above for the resistance selection assay. Stationary phase bacteria were added 411 to the wells to give a final concentration of 5 × 10 5 CFU ml -1 and the microtitre plates incubated 412 statically in air at 37 °C for 18 h. The MIC was defined as the minimum concentration of antibiotic 413 needed to inhibit visible growth of the bacteria [38] . For some assays, fold change in MIC was 414 calculated relative to the MIC of the USA300 ΔagrA mutant which had not been exposed to antibiotics. 
